Avalon Pharmaceuticals to Present on Its Beta-catenin and c-Myc Pathway Inhibitor Programs at the AACR-NCI-EORTC 2007 International Conference
The posters to be presented by Avalon will describe program success against two of the most clinically relevant and historically "undruggable" pathways in cancer: Beta-catenin and c-Myc. The posters are titled:
"Compounds selected and optimized from a biomarker based Beta-catenin pathway screen decrease Beta-catenin protein levels in xenograft tumors, induce a gene expression signature consistent with inhibition of beta-catenin activity, and exhibit anti tumor growth properties." Presentation time: Thursday, October 25, 2007, from 12:30pm-2:30pm and from 5:30pm-7:30pm (PST).
"LC-363: Optimization and in vitro characterization of a novel series of small molecule inhibitors of the Wnt/Beta-catenin signaling pathway." Presentation time: Thursday, October 25, 2007, from 12:30pm-2:30pm and from 5:30pm-7:30pm (PST).
"A biomarker based high throughput screen identifies small molecular weight modulators of the Beta-catenin pathway." Presentation time: Tuesday, October 23, 2007, from 12:30pm-2:30pm and from 5:30pm-7:30pm p.m. (PST).
"Biomarker based high-throughput screening for identification of small molecule inhibitors, targeting the antiproliferative property of the c-Myc signaling pathway." Presentation time: Tuesday, October 23, 2007, from 12:30pm-2:30pm and from 5:30pm-7:30pm p.m. (PST).
About Avalon Pharmaceuticals
Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon's lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the Survivin and Myc pathways and partnerships with Merck, MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx(R) is the company's proprietary platform which is based on large-scale biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, Md.
Safe Harbor Statement
This announcement contains, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect the current views of Avalon management and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, risks and uncertainties, including those specified under the "Risk Factors" section of our 2006 Annual Report on Form 10-K and updates contained in subsequent filings we make with the Securities and Exchange Commission.
Contact
Avalon Pharmaceuticals, Inc.
David D. Muth
Executive Vice President & Chief Business Officer
301-556-9900
Fax: 301-556-9910
info@avalonrx.com
or
Investors:
The Trout Group LLC
Chad Rubin, 646-378-2947
Posted: October 2007
